Pharmacogenetics and anaesthesiology

Current Pharmacogenomics

Volumn 2, Issue 2, 2004, Pages 119-135

  Girard, Thierry ^a   Kindler, Christoph H ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Anaesthesia; Beta adrenergic receptor; Butyrylcholinesterase; Cytochrome P450; Malignant hyperthermia; Opioids; Pharmacogenetics; Pharmacogenomics; Ryanodine receptor; Succinylcholine; Volatile anaesthetics

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; BENZODIAZEPINE; BUTORPHANOL; CHLOROPROCAINE; CHOLINESTERASE; COCAINE; CODEINE; DIAMORPHINE; DIAZEPAM; ENZYME VARIANT; INDOMETACIN; INHALATION ANESTHETIC AGENT; KETAMINE; MIDAZOLAM; MIVACURIUM; NALBUPHINE; NEUROMUSCULAR BLOCKING AGENT; OPIATE; PARACETAMOL; PENTAZOCINE; PROCAINE; PROPOFOL; RYANODINE RECEPTOR; SUXAMETHONIUM; TETRACAINE; TRAMADOL; UNINDEXED DRUG; WARFARIN;

ANESTHESIA COMPLICATION; ANESTHESIOLOGY; ANESTHESIST; APNEA; BLEEDING; BRADYCARDIA; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HUMAN; HYPERKALEMIA; IN VITRO STUDY; LINKAGE ANALYSIS; MALIGNANT HYPERTHERMIA; MOLECULAR GENETICS; MORTALITY; MUSCLE CONTRACTILITY; NONHUMAN; OUTCOMES RESEARCH; PAIN; PERIOPERATIVE PERIOD; PHARMACOGENETICS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROPHYLAXIS; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT;

EID: 3042516985     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570160043377592     Document Type: Review

References (192)

1. Aithal, G. P.; Day, C. P.; Kesteven, P. J. and Daly, A. K. (1999) Association of Polymorphisms in the Cytochrome P450 CYP2C9 with Warfarin Dose Requirement and Risk of Bleeding Complications. Lancet 353, 717-719.
2. Allderdice, P. W.; Gardner, H. A.; Galutira, D.; Lockridge, O.; LaDu, B. N. and McAlpine, P. J. (1991) The Cloned Butyrylcholinesterase (BCHE) Gene Maps to a Single Chromosome Site, 3q26. Genomics 11, 452-454.
3. Allen, G. C. and Brubaker, C. L. (1998) Human Malignant Hyperthermia Associated with Desflurane Anaesthesia. Anesth. Analg. 86, 1328-1331.
4. Allen, P. D. and Lopez, J. R. (2002) "Noninvasive" Testing for Malignant Hyperthermia Susceptibility. Anesthesiology 97, 1045-1046.
5. Anetseder, M.; Hager, M.; Muller, C. R. and Roewer, N. (2002) Diagnosis of Susceptibility to Malignant Hyperthermia by Use of a Metabolic Test. Lancet 359, 1579-1580.
6. Asanuma, K.; Yagihashi, A.; Uehara, N.; Kida, T. and Watanabe, N. (1999) Three Point Mutations of Human Butyrylcholinesterase in a Japanese Family and the Alterations of Three-dimensional Structure. Clin. Chim. Acta 283, 33-42.
7. Barone, V.; Massa, O.; Intravaia, E.; Bracco, A.; Di Martino, A.; Tegazzin, V.; Cozzolino, S. and Sorrentino, V. (1999) Mutation Screening of the RYR1 Gene and Identification of Two Novel Mutations in Italian Malignant Hyperthermia Families. J. Med. Genet. 36, 115-118.
8. Bartels, C. F.; James, K. and La Du, B. N. (1992a) DNA Mutations Associated with the Human Butyrylcholinesterase J-variant. Am. J. Hum. Genet. 50, 1104-1114.
9. Bartels, C. F.; Jensen, F. S.; Lockridge, O.; van der Spek, A. F.; Rubinstein, H. M.; Lubrano, T. and La Du, B. N. (1992b) DNA Mutation Associated with the Human Butyrylcholinesterase K-variant and its Linkage to the Atypical Variant Mutation and Other Polymorphic Sites. Am. J. Hum. Genet. 50, 1086-1103.
10. Befort, K.; Filliol, D.; Decaillot, F. M.; Gaveriaux-Ruff, C.; Hoehe, M. R. and Kieffer, B. L. (2001) A Single Nucleotide Polymorphic Mutation in the Human mu-opioid Receptor Severely Impairs Receptor Signalling. J. Biol. Chem. 276, 3130-3137.
11. Bendixen, D.; Skovgaard, L. T. and Ording, H. (1997) Analysis of Anaesthesia in Patients Suspected to be Susceptible to Malignant Hyperthermia Before Diagnostic In Vitro Contracture Test. Acta Anaesthesiol. Scand. 41, 480-484.
12. Brandt, A.; Schleithoff, L.; Jurkat-Rott, K.; Klingler, W.; Baur, C. and Lehmann-Horn, F. (1999) Screening of the Ryanodine Receptor Gene in 105 Malignant Hyperthermia Families: Novel Mutations and Concordance with the In Vitro Contracture Test. Hum. Mol. Genet. 8, 2055-2062.
13. Brown, R. L.; Pollock, A. N.; Couchman, K. G.; Hodges, M.; Hutchinson, D. O.; Waaka, R.; Lynch, P.; McCarthy, T. V. and Stowell, K. M. (2000) A Novel Ryanodine Receptor Mutation and Genotype-phenotype Correlation in a Large Malignant Hyperthermia New Zealand Maori Pedigree. Hum. Mol. Genet. 9, 1515-1524.
14. Browne, S. P.; Slaughter, E. A.; Couch, R. A.; Rudnic, E. M. and McLean, A. M. (1998) The Influence of Plasma Butyrylcholinesterase Concentration on the In Vitro Hydrolysis of Cocaine in Human Plasma. Biopharm. Drug Dispos. 19, 309-314.
15. Brutsche, M. H. and Joos, L. (2002) A New Dimension for beta2 - Adrenoceptor Gene Polymorphisms. Pharmacogenetics 12, 345-346.
16. Campagna, J. A.; Miller, K. W. and Forman, S. A. (2003) Mechanisms of Actions of Inhaled Anaesthetics. N. Engl. J. Med. 348, 2110-2124.
17. Censier, K.; Urwyler, A.; Zorzato, F. and Treves, S. (1998) Intracellular Calcium Homeostasis in Human Primary Muscle Cells from Malignant Hyperthermia-susceptible and Normal Individuals. Effect of Over-expression of Recombinant Wild-type and Arg 163Cys Mutated Ryanodine Receptors. J. Clin. Invest. 101, 1233-1242.
18. Chamley, D.; Pollock, N. A.; Stowell, K. M. and Brown, R. L. (2000) Malignant Hyperthermia in Infancy and Identification of Novel RYR1 Mutation. Br. J. Anesth. 84, 500-504.
19. Clayton, E. W. (2003) Ethical, Legal and Social Implications of Genomic Medicine. N. Engl. J. Med 349, 562-569.
20. Court, M. H.; Duan, S. X.; Hesse, L. M.; Venkatakrishnan, K. and Greenblatt, D. J. (2001) Cytochrome P-450 2B6 is Responsible for Interindividual Variability of Propofol Hydroxylation by Human Liver Microsomes. Anesthesiology 94, 110-119.
21. Darvesh, S.; Hopkins, D. A. and Geula, C. (2003) Neurobiology of Butyrylcholinesterase. Nat. Rev. Neurosci. 4, 131-138.
22. Delbruck, A. and Henkel, E. (1979) A Rare Genetically Determined Variant of Psuedocholinesterase in Two German Families with High Plasma Enzyme Activity. Eur. J. Biochem. 99, 65-69.
23. Denborough, M. (1960) Anaesthetic Deaths in a Family. Lancet 2, 45.
24. Dishy, V.; Sofowora, G. G.; Xie, H. G.; Kim, R. B.; Byrne, D. W.; Stein, C. M. and Wood, A. J. (2001) The Effect of Common Polymorphisms of the Beta2-adrenergic Receptor on Agonist-mediated Vascular Desensitisation. N. Engl. J. Med. 345, 1030-1035.
25. Donahue, B. S. and Balser, J. R. (2003) Peri-operative Genomics. Venturing into Uncharted Seas. Anesthesiology 99, 7-8.
26. Drabe, N.; Zund, G.; Grunenfelder, J.; Sprenger, M.; Hoerstrup, S. P.; Bestmann, L.; Maly, F. E. and Turina, M. (2001) Genetic Predisposition in Patients Undergoing Cardiopulmonary Bypass Surgery is Associated with an Increase of Inflammatory Cytokines. Eur. J. Cardiothorac. Surg. 20, 609-613.
27. Ellis, F. R.; Harriman, D. G.; Keaney, N. P.; Kyei-Mensah, K. and Tyrrell, J. H. (1971) Halothane-induced Muscle Contracture as a Cause of Hyperpyrexia. Br. J. Anesth. 43, 721-722.
28. European Malignant Hyperpyrexia Group (1984) A Protocol for the Investigation of Malignant Hyperpyrexia (MH) Susceptibility. Br. J. Anesth. 56, 1267-1269.
29. Evans, R. T. and Wardell, J. (1984) On the Identification and Frequency of the J and K Cholinesterase Phenotypes in a Caucasian Population. J. Med. Genet. 21, 99-102.
30. Evans, W. E. and McLeod, H. L. (2003) Pharmacogenomics - drug Disposition, Drug Targets and Side Effects. N. Engl. J. Med. 348, 538-549.
31. Evans, W. E. and Relling, M. V. (1999) Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 286, 487-491.
32. Fagerlund, T. H. and Braaten, O. (2001) No Pain Relief from Codeine...? An Introduction to Pharmacogenomics. Acta Anaesthesiol. Scand. 45, 140-149.
33. Fellay, J.; Marzolini, C.; Meaden, E. R.; Back, D. J.; Buclin, T.; Chave, J. P.; Decosterd, L. A.; Furrer, H.; Opravil, M.; Pantaleo, G.; Retelska, D.; Ruiz, L.; Schinkel, A. H.; Vernazza, P.; Eap, C. B. and Telenti, A. (2002) Response to Antiretroviral Treatment in HIV-1-infected Individuals with Allelic Variants of the Multidrug Resistance Transporter 1: A Pharmacogenetics Study. Lancet 359, 30-36.
34. Ferrari, P. and Bianchi, G. (2000) The Genomics of Cardiovascular Disorders: Therapeutic Implications. Drugs 59, 1025-1042.
35. Fujii, J.; Otsu, K.; Zorzato, F.; de Leon, S.; Khanna, V. K.; Weiler, J. E.; O'Brien, P. J. and MacLennan, D. H. (1991) Identification of a Mutation in Porcine Ryanodine Receptor Associated with Malignant Hyperthermia. Science 253, 448-451.
36. Galli, L.; Orrico, A.; Cozzolino, S.; Pietrini, V.; Tegazzin, V. and Sorrentino, V. (2002) Mutations in the RYR1 Gene in Italian Patients at Risk for Malignant Hyperthermia: Evidence for a Cluster of Novel Mutations in the C-terminal Region. Cell Calcium 32, 143-151.
37. Gamo, S.; Dodo, K.; Matakatsu, H. and Tanaka, Y. (1998) Molecular Genetical Analysis of Drosophila Ether Sensitive Mutants. Toxicol. Lett. 100-101, 329-337.
38. Gamo, S.; Tomida, J.; Dodo, K.; Keyakidani, D.; Matakatsu, H.; Yamamoto, D. and Tanaka, Y. (2003) Calreticulin Mediates Anaesthetic Sensitivity in Drosophila Melanogaster. Anesthesiology 99, 867-875.
39. Gatke, M. R., Ostergaard, D.; Bundgaard, J. R.; Varin, F. and Viby-Mogensen, J. (2001) Response to Mivacurium in a Patient Compound Heterozygous for a Novel and a Known Silent Mutation in the Butyrylcholinesterase Gene: Genotyping by Sequencing. Anesthesiology 95, 600-606.
40. Gaughan, G.; Park, H.; Priddle, J.; Craig, I. and Craig, S. (1991) Refinement of the Localisation of Human Butyrylcholinesterase to Chromosome 3q26.1-q26.2 Using a PCR-derived Probe. Genomics 11, 455-458.
41. Gear, R. W.; Miaskowski, C.; Gordon, N. C.; Paul, S. M.; Heller, P. H. and Levine, J. D. (1996) Kappa-opioids Produce Significantly Greater Analgesia in Women than in Men. Nat. Med. 2, 1248-1250.
42. Gear, R. W.; Miaskowski, C.; Gordon, N. C.; Paul, S. M.; Heller, P. H. and Levine, J. D. (1999) The kappa Opioid Nalbuphine Produces Gender- and Dose-dependent Analgesia and Antianalgesia in Patients with Postoperative Pain. Pain 83, 339-345.
43. Gillard, E. F.; Otsu, K.; Fujii, J.; Duff, C.; de Leon, S.; Khanna, V. K.; Britt, B. A.; Worton, R. G. and MacLennan, D. H. (1992) Polymorphisms and Deduced Amino Acid Substitutions in the Coding Sequence of the Ryanodine Receptor (RYR1) Gene in Individuals with Malignant Hyperthermia. Genomics 13, 1247-1254.
44. Gillard, E. F.; Otsu, K.; Fujii, J.; Khanna, V. K., de Leon, S.; Derdemezi, J.; Britt, B. A.; Duff, C. L.; Worton, R. G. and MacLennan, D. H. (1991) A Substitution of Cysteine for Arginine 614 in the Ryanodine Receptor is Potentially Causative of Human Malignant Hyperthermia. Genomics 11, 751-755.
45. Girard, T.; Cavagna, D.; Padovan, E.; Spagnoli, G.; Urwyler, A.; Zorzato, F. and Treves, S. (2001) B-lymphocytes from Malignant Hyperthermia-susceptible Patients have an Increased Sensitivity to Skeletal Muscle Ryanodine Receptor Activators. J. Biol. Chem. 276, 48077-48082.
46. Girard, T.; Ginz, H. F.; Voronkov, E.; Buehler, E. and Urwyler, A. (2003) Cholinesterase Deficiency: Identification of a Novel Mutation (Abstract). Anesth. Analg. 96, S-241.
47. Girard, T.; Treves, S.; Censier, K.; Mueller, C. R.; Zorzato, F. and Urwyler, A. (2002) Phenotyping Malignant Hyperthermia Susceptibility by Measuring Halothane-induced Changes in Myoplasmic Calcium Concentration in Cultured Human Skeletal Muscle Cells. Br. J. Anesth. 89, 571-579.
48. Goering, M. and Agarwal, K., (2000) A Historical Review on Malignant Hypethermia. In Malignant Hyperthermia, Wappler, F. Ed., Pabst Science Publishers, Lengerich, pp. 14-24.
49. Goulden, M. R. and Hunter, J. M. (1999) Rapacuronium (Org 9487): Do We Have a Replacement for Succinylcholine? Br. J. Anesth. 82, 489-492.
50. Greenberg, C. P.; Primo-Parmo, S. L.; Pantuck, E. J. and la Du, B. N. (1995) Prolonged Response to Succinylcholine: A New Variant of Plasma Cholinesterase that is Identified as Normal by Traditional Phenotyping Methods. Anesth. Analg. 81, 419-421.
51. Gronert, G.; Antonigni, J. and Pessah, I., (2000) Malignant Hyperthermia. In Anaesthesia, Miller, R. Ed., Churchill Livingstone, New York, pp, 1033-1052.
52. Harris, H. and Whittaker, M. (1961) Differential Inhibition of Human Serum Cholinesterase with Fluoride: Recognition of Two New Phenotypes. Nature 191, 496-498.
53. Harrison, G. G. (1975) Control of the Malignant Hyperpyrexic Syndrome in MHS Swine by Dantrolene Sodium. Br. J. Anesth. 47, 62-65.
54. Healy, S. J.; Heffron, J. J.; Lehane, M.; Bradley, D. G.; Johnson, K. and McCarthy, T. V. (1991) Diagnosis of Susceptibility to Malignant Hyperthermia with Flanking DNA Markers. B.M.J. 303, 1225-1228.
55. Hidaka, K.; Iuchi, I.; Tomita, M.; Watanabe, Y.; Minatogawa, Y.; Iwasaki, K.; Gotoh, K. and Shimizu, C. (1997) Genetic Analysis of a Japanese Patient with Butyrylcholinesterase Deficiency. Ann. Hum. Genet. 61 (Pt 6), 491-496.
56. Hoffman, R. S.; Henry, G. C.; Howland, M. A.; Weisman, R. S.; Weil, L. and Goldfrank, L. R. (1992) Association Between Life-threatening Cocaine Toxicity and Plasma Cholinesterase Activity. Ann. Emerg. Med. 21, 247-253.
57. Hopkins, P. M.; Halsall, P. J. and Ellis, F. R. (1994) Diagnosing Malignant Hyperthermia Susceptibility. Anaesthesia 49, 373-375.
58. Iaizzo, P. A.; Klein, W. and Lehmann-Horn, F. (1988) Fura-2 Detected Myoplasmic Calcium and its Correlation with Contracture Force in Skeletal Muscle from Normal and Malignant Hyperthermia Susceptible Pigs. Pflugers Arch. 411, 648-653.
59. Iaizzo, P. A. and Lehmann-Horn, F. (1995) Anaesthetic Complications in Muscle Disorders. Anesthesiology 82, 1093-1096.
60. Iles, D. E.; Lehmann-Horn, F.; Scherer, S. W.; Tsui, L. C.; Olde Weghuis, D.; Suijkerbuijk, R. F.; Heytens, L.; Mikala, G.; Schwartz, A.; Ellis, F. R.; Stewart, A. D. and Wieringa, B. (1994) Localization of the Gene Encoding the Alpha 2/delta-subunits of the L- type Voltage-dependent Calcium Channel to Chromosome 7q and Analysis of the Segregation of Flanking Markers in Malignant Hyperthermia Susceptible Families. Hum. Mol. Genet. 3, 969-975.
61. Ingelman-Sundberg, M. (2001) Pharmacogenetics: An Opportunity for a Safer and More Efficient Pharmacotherapy. J. Intern. Med. 250, 186-200.
62. Ingelman-Sundberg, M. (2003) Human Drug Metabolising Cytochrome P450 Enzymes: Properties and Polymorphisms. Naunyn. Schmiedebergs. Arch. Pharmacol., in press.
63. Ingelman-Sundberg, M. and Evans, W. E. (2001) Unravelling the Functional Genomics of the Human CYP2D6 Gene Locus. Pharmacogenetics 11, 553-554.
64. Israel, E.; Drazen, J. M.; Liggett, S. B.; Boushey, H. A.; Cherniack, R. M.; Chinchilli, V. M.; Cooper, D. M.; Fahy, J. V.; Fish, J. E.; Ford, J. G.; Kraft, M.; Kunselman, S.; Lazarus, S. C.; Lemanske, P. F.; Martin, R. J.; McLean, D. E.; Peters, S. P.; Silverman, E. K.; Sorkness, C. A.; Szefler, S. J.; Weiss, S. T. and Yandava, C. N. (2000) The Effect of Polymorphisms of the Beta(2)-adrenergic Receptor on the Response to Regular Use of Albuterol in Asthma. Am. J. Respir. Crit. Care. Med. 162, 75-80.
65. Jensen, F. S.; Bartels, C. F. and La Du, B. N. (1992) Structural Basis of the Butyrylcholinesterase H-variant Segregating in Two Danish Families. Pharmacogenetics 2, 234-240.
66. Jensen, F. S.; Schwartz, M. and Viby-Mogensen, J. (1995a) Identification of Human Plasma Cholinesterase Variants Using Molecular Biological Techniques. Acta. Anaesthesiol. Scand. 39, 142-149.
67. Jensen, F. S.; Skovgaard, L. T. and Viby-Mogensen, J. (1995b) Identification of Human Plasma Cholinesterase Variants in 6,688 Individuals Using Biochemical Analysis. Acta. Anaesthesiol. Scand. 39, 157-162.
68. Johnson, J. A.; Zineh, I.; Puckett, B. J.; McGorray, S. P.; Yarandi, H. N. and Pauly, D. F. (2003) Beta 1-adrenergic Receptor Polymorphisms and Antihypertensive Response to Metoprolol. Clin. Pharmacol. Ther. 74, 44-52.
69. Jurkat-Rott, K.; McCarthy, T. and Lehmann-Horn, F. (2000) Genetics and Pathogenesis of Malignant Hyperthermia. Muscle Nerve 23, 4-17.
70. Kalow, W. (1959) The Distribution, Destruction and Elimination of Muscle Relaxants. Anesthesiology 20, 505-518.
71. Kalow, W. (1990) Pharmacogenetics: Past and Future. Life Sci. 47, 1385-1397.
72. Kalow, W.; Britt, B. A.; Terreau, M. E. and Haist, C. (1970) Metabolic Error of Muscle Metabolism After Recovery from Malignant Hyperthermia. Lancet 2, 895-898.
73. Kalow, W. and Genest, K. (1957) A method for the detecion of atypical forms of human serum cholinesterase. Determination of dibucaine numbers. Can. J. Biochem. Physiol. 35, 339-346.
74. Kalow, W. and Gunn, D. (1957) The Relation Between Dose of Succinylcholine and Duration of Apnea in Man. J. Pharmacol. Exp. Ther. 120, 203-214.
75. Kalow, W. and Lindsay, H. A. (1955) A Comparison of Optical and Manometric Methods for the Assay of Human Serum Cholinesterase. Can. J. Biochem. Physiol. 35, 339-346.
76. Kayser, E. B.; Morgan, P. G. and Sedensky, M. M. (1999) GAS-1: A Mitochondrial Protein Controls Sensitivity to Volatile Anaesthetics in the Nematode Caenorhabditis Elegans. Anesthesiology 90, 545-554.
77. Keating, K. E.; Giblin, L.; Lynch, P. J.; Quane, K. A.; Lehane, M.; Heffron, J. J. and McCarthy, T. V. (1997) Detection of a Novel Mutation in the Ryanodine Receptor Gene in an Irish Malignant Hyperthermia Pedigree: Correlation of the IVCT Response with the Affected and Unaffected Haplotypes. J. Med. Genet. 34, 291-296.
78. Keating, K. E.; Quane, K. A.; Manning, B. M.; Lehane, M.; Hartung, E.; Censier, K.; Urwyler, A.; Klausnitzer, M.; Muller, C. R. and Heffron, J. J. (1994) Detection of a Novel RYR1 Mutation in Four Malignant Hyperthermia Pedigrees. Hum. Mol. Genet. 3, 1855-1858.
79. Klingler, W.; Baur, C.; Georgieff, M.; Lehmann-Horn, F. and Melzer, W. (2002) Detection of Proton Release from Cultured Human Myotubes to Identify Malignant Hyperthermia Susceptibility. Anesthesiology 97, 1059-1066.
80. Kofke, W. A.; Konitzer, P.; Meng, Q. C. and Guo, J. (2003) Effect of Apolipoprotein E Genotype on NSE and S-100 Levels after Cardiac and Vascular Surgery. Anesthesiology 99, A357.
81. Krause, A.; Lane, A. B. and Jenkins, T. (1988) A New High Activity Plasma Cholinesterase Variant. J. Med. Genet. 25, 677-681.
82. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P. B.; Daly, A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M. S. and Schuetz, E. (2001) Sequence Diversity in CYP3A Promoters and Characterisation of the Genetic Basis of Polymorphic CYP3A5 Expression. Nat. Genet. 27, 383-391.
83. La Du, B. N. (1995) Butyrylcholinesterase Variants and the New Methods of Molecular Biology. Acta Anaesthesiol. Scand. 39, 139-141.
84. La Du, B. N.; Bartels, C. F.; Nogueira, C. P.; Hajra, A.; Lightstone, H.; Van der Spek, A. and Lockridge, O. (1990) Phenotypic and Molecular Biological Analysis of Human Butyrylcholinesterase Variants. Clin. Biochem. 23, 423-431.
85. Landau, R.; Xie, H. G.; Dishy, V.; Stein, C. M.; Wood, A. J.; Emala, C. W. and Smiley, R. M. (2002) beta2-Adrenergic Receptor Genotype and Preterm Delivery. Am. J. Obstet. Gynecol. 187, 1294-1298.
86. Larach, M. G. (1989) Standardisation of the Caffeine Halothane Muscle Contracture Test. North American Malignant Hyperthermia Group. Anesth. Analg. 69, 511-515.
87. Larach, M. G.; Localio, A. R.; Allen, G. C.; Denborough, M. A.; Ellis, F. R.; Gronert, G. A.; Kaplan, R. F.; Muldoon, S. M.; Nelson, T. E., Ording, H.; Rosenberg, H.; Waud, B. E. and Wedel, D. J. (1994) A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility. Anesthesiology 80, 771-779.
88. Lasocki, S.; Iglarz, M.; Seince, P. F.; Vuillaumier-Barrot, S.; Vicaut, E.; Henrion, D.; Levy, B.; Desmonts, J. M.; Philip, I. and Benessiano, J. (2002) Involvement of Renin-angiotensin System in Pressure-flow Relationship: Role of Angiotensin-converting Enzyme Gene Polymorphism. Anesthesiology 96, 271-275.
89. Lazarou, J.; Pomeranz, B. H. and Corey, P. N. (1998) Incidence of Adverse Drug Reactions in Hospitalised Patients: A Meta-analysis of Prospective Studies. JAMA 279, 1200-1205.
90. Liddell, J.; Lehmann, H. and Silk, E. (1962) A 'Silent' Pseudocholinesterase Gene. Nature 193, 561-562.
91. Liggett, S. B. (2000) The Pharmacogenetics of beta2-Adrenergic Receptors: Relevance to Asthma. J. Allergy Clin. Immunol. 105, S487-492.
92. Lima, J. J.; Thomason, D. B.; Mohamed, M. H.; Eberle, L. V.; Self, T. H. and Johnson, J. A. (1999) Impact of Genetic Polymorphisms of the beta2-Adrenergic Receptor on Albuterol Bronchodilator Pharmacodynamics. Clin. Pharmacol. Ther. 65, 519-525.
93. Liu, J.; Liu, Z. Q.; Tan, Z. R.; Chen, X. P.; Wang, L. S.; Zhou, G. and Zhou, H. H. (2003) Gly389Arg Polymorphism of beta1-Adrenergic Receptor is Associated with the Cardiovascular Response to Metoprolol. Clin. Pharmacol. Ther. 74, 372-379.
94. Lockridge, O.; Bartels, C. F.; Vaughan, T. A.; Wong, C. K.; Norton, S. E. and Johnson, L. L. (1987) Complete Amino Acid Sequence of Human Serum Cholinesterase. J. Biol. Chem. 262, 549-557.
95. Lubin, A. H.; Garry, P. J. and Owen, G. M. (1971) Sex and Population Differences in the Incidence of a Plasma Cholinesterase Variant. Science 173, 161-164.
96. Lynch, P. J.; Krivosic-Horber, R.; Reyford, H.; Monnier, N.; Quane, K.; Adnet, P.; Haudecoeur, G.; Krivosic, I.; McCarthy, T. and Lunardi, J. (1997) Identification of Heterozygous and Homozygous Individuals with the Novel RYR1 Mutation Cys35Arg in a Large Kindred. Anesthesiology 86, 620-626.
97. Lynch, P. J.; Tong, J.; Lehane, M.; Mallet, A.; Giblin, L.; Heffron, J. J.; Vaughan, P.; Zafra, G.; MacLennan, D. H. and McCarthy, T. V. (1999) A Mutation in the Transmembrane/luminal Domain of the Ryanodine Receptor is Associated with Abnormal Ca2+ Release Channel Function and Severe Central Core Disease. Proc. Natl. Acad. Sci. USA 96, 4164-4169.
98. Mack, A. and Robitzki, A. (2000) The Key Role of Butyrylcholinesterase During Neurogenesis and Neural Disorders: An Antisense-5′butyrylcholinesterase-DNA Study. Prog. Neurobiol. 60, 607-628.
99. MacLennan, D. H.; Duff, C.; Zorzato, F.; Fujii, J.; Phillips, M.; Korneluk, R. G.; Frodis, W.; Britt, B. A. and Worton, R. G. (1990) Ryanodine Receptor Gene is a Candidate for Predisposition to Malignant Hyperthermia. Nature 343, 559-561.
100. MacLennan, D. H. and Phillips, M. S. (1992) Malignant Hyperthermia. Science 256, 789-794.
101. Manning, B. M.; Quane, K. A.; Lynch, P. J.; Urwyler, A.; Tegazzin, V.; Krivosic-Horber, R.; Censier, K.; Comi, G.; Adnet, P.; Wolz, W.; Lunardi, J.; Muller, C. R. and McCarthy, T. V. (1998a) Novel Mutations at a Cpg Dinucleotide in the Ryanodine Receptor in Malignant Hyperthermia. Hum. Mutat. 11, 45-50.
102. Manning, B. M.; Quane, K. A.; Ording, H.; Urwyler, A.; Tegazzin, V.; Lehane, M.; O'Halloran, J.; Hartung, E.; Giblin, L. M.; Lynch, P. J.; Vaughan, P.; Censier, K.; Bendixen, D.; Comi, G.; Heytens, L.; Monsieurs, K.; Fagerlund, T.; Wolz, W.; Heffron, J. J.; Muller, C. R. and McCarthy, T. V. (1998b) Identification of Novel Mutations in the Ryanodine-Receptor Gene (RYR1) in Malignant Hyperthermia: Genotype-Phenotype Correlation. Am. J. Hum. Genet. 62, 599-609.
103. Martinez, F. D.; Graves, P. E.; Baldini, M.; Solomon, S. and Erickson, R. (1997) Association Between Genetic Polymorphisms of the beta2-Adrenoceptor and Response to Albuterol in Children with and without a History of Wheezing. J. Clin. Invest. 100, 3184-3188.
104. Mathew, J. P.; Rinder, C. S.; Howe, J. G.; Fontes, M.; Crouch, J.; Newman, M. F.; Phillips-Bute, B. and Smith, B. R. (2001) Platelet PlA2 Polymorphism Enhances Risk of Neurocognitive Decline after Cardiopulmonary Bypass. Multicentre Study of Peri-operative Ischemia (McSPI) Research Group. Ann. Thorac. Surg. 71, 663-666.
105. Mayer, P.; Rochlitz, H.; Rauch, E.; Rommelspacher, H.; Hasse, H. E.; Schmidt, S. and Hollt, V. (1997) Association Between a delta Opioid Receptor Gene Polymorphism and Heroin Dependence in Man. Neuroreport 8, 2547-2550.
106. McCarthy, T. V.; Healy, J. M.; Heffron, J. J.; Lehane, M.; Deufel, T.; Lehmann-Horn, F.; Farrall, M. and Johnson, K. (1990) Localization of the Malignant Hyperthermia Susceptibility Locus to Human Chromosome 19q12-13.2. Nature 343, 562-564.
107. McCarthy, T. V.; Quane, K. A. and Lynch, P. J. (2000) Ryanodine Receptor Mutations in Malignant Hyperthermia and Central Core Disease. Hum. Mutat. 15, 410-417.
108. McGuire, M. C.; Nogueira, C. P.; Bartels, C. F.; Lightstone, H.; Hajra, A.; Van der Spek, A. F.; Lockridge, O. and La Du, B. N. (1989) Identification of the Structural Mutation Responsible for the Dibucaine-Resistant (Atypical) Variant Form of Human Serum Cholinesterase. Proc. Natl. Acad. Sci. USA 86, 953-957.
109. Meyer, U. A., (2000a) Drugs in Special Patient Groups: Clinical Importance of Genomics in Drug Effects. In Clinical pharmacology, Carruthers, G. S.; Hoffmann, B. B.; Melmon, K. L. and Nierenberg, D. W. Eds., McGrawHill, New York, pp. 1179-1205.
110. Meyer, U. A. (2000b) Pharmacogenetics and Adverse Drug Reactions. Lancet 356, 1667-1671.
111. Mickelson, J. R.; Gallant, E. M.; Litterer, L. A.; Johnson, K. M.; Rempel, W. E. and Louis, C. F. (1988) Abnormal Sarcoplasmic Reticulum Ryanodine Receptor in Malignant Hyperthermia. J. Biol. Chem. 263, 9310-9315.
112. Miners, J. O. and Birkett, D. J. (1998) Cytochrome P4502C9: an Enzyme of Major Importance in Human Drug Metabolism. Br. J. Clin. Pharmacol. 45, 525-538.
113. Mogil, J. S. (1999a) The Genetic Mediation of Individual Differences in Sensitivity to Pain and its Inhibition. Proc. Natl. Acad. Sci. USA 96, 7744-7751.
114. Mogil, J. S.; Wilson, S. G.; Bon, K.; Lee, S. E.; Chung, K.; Raber, P.; Pieper, J. O.; Hain, H. S.; Belknap, J. K.; Hubert, L.; Elmer, G. I.; Chung, J. M. and Devor, M. (1999b) Heritability of Nociception I: Responses of 11 Inbred Mouse Strains on 12 Measures of Nociception. Pain 80, 67-82.
115. Mogil, J. S.; Wilson, S. G.; Bon, K.; Lee, S. E.; Chung, K.; Raber, P.; Pieper, J. O.; Hain, H. S.; Belknap, J. K.; Hubert, L.; Elmer, G. I.; Chung, J. M. and Devor, M. (1999c) Heritability of Nociception II. 'Types' of Nociception Revealed by Genetic Correlation Analysis. Pain 80, 83-93.
116. Monnier, N.; Krivosic-Horber, R.; Payen, J. F.; Kozak-Ribbens, G.; Nivoche, Y.; Adnet, P.; Reyford, H. and Lunardi, J. (2002) Presence of Two Different Genetic Traits in Malignant Hyperthermia Families: Implication for Genetic Analysis, Diagnosis and Incidence of Malignant Hyperthermia Susceptibility. Anesthesiology 97, 1067-1074.
117. Monnier, N.; Procaccio, V.; Stieglitz, P. and Lunardi, J. (1997) Malignant-Hyperthermia Susceptibility is Associated with a Mutation of the alpha 1-Subunit of the Human Dihydropyridine-Sensitive L-Type Voltage- Dependent Calcium-Channel Receptor in Skeletal Muscle. Am. J. Hum. Genet. 60, 1316-1325.
118. Monnier, N.; Romero, N. B.; Lerale, J.; Landrieu, P.; Nivoche, Y.; Fardeau, M. and Lunardi, J. (2001) Familial and Sporadic Forms of Central Core Disease are Associated with Mutations in the C-Terminal Domain of the Skeletal Muscle Ryanodine Receptor. Hum. Mol. Genet. 10, 2581-2592.
119. Monnier, N.; Romero, N. B.; Lerale, J.; Nivoche, Y.; Qi, D.; MacLennan, D.H.; Fardeau, M. and Lunardi, J. (2000) An Autosomal Dominant Congenital Myopathy with Cores and Rods is Associated with a Neomutation in the RYR1 Gene Encoding the Skeletal Muscle Ryanodine Receptor. Hum. Mol. Genet. 9, 2599-2608.
120. Moschcowitz, A. (1916) Postoperative Heat Stroke. Surg. Gynecol. Obstet. 23, 441-451.
121. Motamed, C.; Kirov, K.; Combes, X.; Dhonneur, G. and Duvaldestin, P. (2002) Effect of Metoclopramide on Mivacurium-Induced Neuromuscular Block. Acta Anaesthesiol. Scand. 46, 214-216.
122. Navis, G.; van der Kleij, F. G.; de Zeeuw, D. and de Jong, P. E. (1999) Angiotensin-converting Enzyme Gene I/D Polymorphism and Renal Disease. J. Mol. Med. 77, 781-791.
123. Nogueira, C. P.; Bartels, C. F.; McGuire, M. C.; Adkins, S.; Lubrano, T.; Rubinstein, H. M.; Lightstone, H.; Van der Spek, A. F.; Lockridge, O. and La Du, B. N. (1992) Identification of Two Different Point Mutations Associated with the Fluoride-Resistant Phenotype for Human Butyrylcholinesterase. Am. J. Hum. Genet. 51, 821-828.
124. Nogueira, C. P.; McGuire, M. C.; Graeser, C.; Bartels, C. F.; Arpagaus, M.; Van der Spek, A. F.; Lightstone, H.; Lockridge, O. and La Du, B. N. (1990) Identification of a Frameshift Mutation Responsible for the Silent Phenotype of Human Serum Cholinesterase, Gly 117 (GGT----GGAG). Am. J. Hum. Genet. 46, 934-942.
125. Oda, Y.; Hamaoka, N.; Hiroi, T.; Imaoka, S.; Hase, I.; Tanaka, K.; Funae, Y.; Ishizaki, T. and Asada, A. (2001) Involvement of Human Liver Cytochrome P4502B6 in the Metabolism of Propofol. Br. J. Clin. Pharmacol. 51, 281-285.
126. Ording, H. (1988) Diagnosis of Susceptibility to Malignant Hyperthermia in Man. Br. J. Anesth. 60, 287-302.
127. Ording, H. (1996) Investigation of Malignant Hyperthermia Susceptibility in Denmark. Dan. Med. Bull. 43, 111-125.
128. Ording, H.; Brancadoro, V.; Cozzolino, S.; Ellis, F. R.; Glauber, V.; Gonano, E. F.; Halsall, P. J.; Hartung, E.; Heffron, J. J.; Hytens, L.; Kozak-Ribbens, G.; Kress, H.; Krivosic-Horber, R.; Lehmann-Horn, F.; Mortier, W.; Nivoche, Y.; Ranklev-Twetman, E.; Sigurdsson, S.; Snoeck, M.; Stieglitz, P.; Tegazzin, V.; Urwyler, A. and Wappler, F. (1997) In Vitro Contracture Test for Diagnosis of Malignant Hyperthermia Following the Protocol of the European MH Group: Results of Testing Patients Surviving Fulminant MH and Unrelated Low-Risk Subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol. Scand. 41, 955-966.
129. Oyamada, H.; Oguchi, K.; Saitoh, N.; Yamazawa, T.; Hirose, K.; Kawana, Y.; Wakatsuki, K.; Tagami, M.; Hanaoka, K.; Endo, M. and Iino, M. (2002) Novel Mutations in C-Terminal Channel Region of the Ryanodine Receptor in Malignant Hyperthermia Patients. Jpn. J. Pharmacol. 88, 159-166.
130. Pantuck, E. J. (1993) Plasma Cholinesterase: Gene and Variations. Anesth. Analg. 77, 380-386.
131. Pessah, I. and PD, A., (2000) Calcium Regulation. In Malignant Hyperthermia, Wappler, F. Ed., Pabst Science Publishers, Lengerich, pp. 98-106.
132. Phillips, K. A.; Veenstra, D. L.; Oren, E.; Lee, J. K. and Sadee, W. (2001) Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review. Jama 286, 2270-2279.
133. Phillips, M. S.; Fujii, J.; Khanna, V. K.; DeLeon, S.; Yokobata, K.; de Jong, P. J. and MacLennan, D. H. (1996) The Structural Organization of the Human Skeletal Muscle Ryanodine Receptor (RYR1) Gene. Genomics 34, 24-41.
134. Poldermans, D.; Boersma, E.; Bax, J. J.; Thomson, I. R.; van de Ven, L. L.; Blankensteijn, J. D.; Baars, H. F.; Yo, T. I.; Trocino, G.; Vigna, C.; Roelandt, J. R. and van Urk, H. (1999) The Effect of Bisoprolol on Peri-operative Mortality and Myocardial Infarction in High-Risk Patients Undergoing Vascular Surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N. Engl. J. Med. 341, 1789-1794.
135. Poulsen, L.; Arendt-Nielsen, L.; Brosen, K. and Sindrup, S. H. (1996) The Hypoalgesic Effect of Tramadol in Relation to CYP2D6. Clin. Pharmacol. Ther. 60, 636-644.
136. Primo-Parmo, S. L.; Bartels, C. F.; Wiersema, B.; van der Spek, A. F.; Innis, J. W. and La Du, B. N. (1996) Characterization of 12 Silent Alleles of the Human Butyrylcholinesterase (BCHE) Gene. Am. J. Hum. Genet. 58, 52-64.
137. Priori, S. G.; Barhanin, J.; Hauer, R. N.; Haverkamp, W.; Jongsma, H. J.; Kleber, A. G.; McKenna, W. J.; Roden, D. M.; Rudy, Y.; Schwartz, K.; Schwartz, P. J.; Towbin, J. A. and Wilde, A. M. (1999a) Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Parts I and II. Circulation 99, 518-528.
138. Priori, S. G.; Napolitano, C. and Schwartz, P. J. (1999b) Low Penetrance in the Long-QT Syndrome: Clinical Impact. Circulation 99, 529-533.
139. Puschel, K.; Schubert-Thiele, I.; Hirth, L.; Benkmann, H. G. and Brinkmann, B. (1978) Malignant Hyperthermia during the 13th General Anaesthesia. Anaesthesist 27, 488-491.
140. Quane, K. A.; Healy, J. M.; Keating, K. E.; Manning, B. M.; Couch, F. J.; Palmucci, L. M.; Doriguzzi, C.; Fagerlund, T. H.; Berg, K.; Ording, H.; Bendixen, D.; Mortier, W.; Linz, U.; Muller, C. R. and McCarthy, T. V. (1993) Mutations in the Ryanodine Receptor Gene in Central Core Disease and Malignant Hyperthermia. Nat. Genet. 5, 51-55.
141. Quane, K. A.; Keating, K. E.; Healy, J. M.; Manning, B. M.; Krivosic-Horber, R.; Krivosic, I.; Monnier, N.; Lunardi, J. and McCarthy, T. V. (1994a) Mutation Screening of the RYR1 Gene in Malignant Hyperthermia: Detection of a Novel Tyr to Ser Mutation in a Pedigree with Associated Central Cores. Genomics 23, 236-239.
142. Quane, K. A.; Keating, K. E.; Manning, B. M.; Healy, J. M.; Monsieurs, K.; Heffron, J. J.; Lehane, M.; Heytens, L.; Krivosic-Horber, R. and Adnet, P. (1994b) Detection of a Novel Common Mutation in the Ryanodine Receptor Gene in Malignant Hyperthermia: Implications for Diagnosis and Heterogeneity Studies. Hum. Mol. Genet. 3, 471-476.
143. Quane, K. A.; Ording, H.; Keating, K. E.; Manning, B. M.; Heine, R.; Bendixen, D.; Berg, K.; Krivosic-Horber, R.; Lehmann-Horn, F.; Fagerlund, T. and McCarthy, T. V. (1997) Detection of a Novel Mutation at Amino Acid Position 614 in the Ryanodine Receptor in Malignant Hyperthermia. Br. J. Anesth. 79, 332-337.
144. Quinlan, J. J.; Homanics, G. E. and Firestone, L. L. (1998) Anaesthesia Sensitivity in Mice that Lack the Beta3 Subunit of the Gamma-Aminobutyric Acid Type A Receptor. Anesthesiology 88, 775-780.
145. Rajaram, S. and Morgan, P. G. (2003) A Glimpse into the many Possibilities that Lie Ahead. Anesthesiology 99, 771-773.
146. Rajaram, S.; Sedensky, M. M. and Morgan, P. G. (1998) Unc-1: A Stomatin Homologue Controls Sensitivity to Volatile Anaesthetics in Caenorhabditis Elegans. Proc. Natl. Acad. Sci. USA 95, 8761-8766.
147. Rinder, C. S.; Mathew, J. P.; Rinder, H. M.; Greg Howe, J.; Fontes, M.; Crouch, J.; Pfau, S.; Patel, P. and Smith, B. R. (2002) Platelet PlA2 Polymorphism and Platelet Activation are associated with Increased Troponin I Release after Cardiopulmonary Bypass. Anesthesiology 97, 1118-1122.
148. Risch, N. and Merikangas, K. (1996) The Future of Genetic Studies of Complex Human Diseases. Science 273, 1516-1517.
149. Robinson, R.; Curran, J. L.; Hall, W. J.; Halsall, P. J.; Hopkins, P. M.; Markham, A. F.; Stewart, A. D.; West, S. P. and Ellis, F. R. (1998) Genetic Heterogeneity and HOMOG Analysis in British Malignant Hyperthermia Families. J. Med. Genet. 35, 196-201.
150. Robinson, R.; Hopkins, P.; Carsana, A.; Gilly, H.; Halsall, J.; Heytens, L.; Islander, G.; Jurkat-Rott, K.; Muller, C. and Shaw, M. A. (2003a) Several Interacting Genes Influence the Malignant Hyperthermia Phenotype. Hum. Genet. 112, 217-218.
151. Robinson, R. L.; Anetseder, M. J.; Brancadoro, V.; Van Broekhoven, C.; Carsana, A.; Censier, K.; Fortunato, G.; Girard, T.; Heytens, L.; Hopkins, P. M.; Jurkat-Rott, K.; Klinger, W.; Kozak-Ribbens, G.; Krivosic, R.; Monnier, N.; Nivoche, Y.; Olthoff, D.; Rueffert, H.; Sorrentino, V.; Tegazzin, V. and Mueller, C. R. (2003b) Recent Advances in the Diagnosis of Malignant Hyperthermia Susceptibility: How Confident can we be of Genetic Testing? Eur. J. Hum. Genet. 11, 342-348.
152. Robinson, R. L.; Curran, J. L.; Ellis, F. R.; Halsall, J.; Hall, W. J.; Hopkins, P. M.; Iles, D. E.; West, S. P. and Shaw, M. A. (2000) Multiple Interacting Gene Products may Influence Susceptibility to Malignant Hyperthermia. Ann. Hum. Genet. 64, 307-320.
153. Robinson, R. L.; Monnier, N.; Wolz, W.; Jung, M.; Reis, A.; Nuernberg, G.; Curran, J. L.; Monsieurs, K.; Stieglitz, P.; Heytens, L.; Fricker, R.; van Broeckhoven, C.; Deufel, T.; Hopkins, P. M.; Lunardi, J. and Mueller, C. R. (1997) A Genome Wide Search for Susceptibility Loci in Three European Malignant Hyperthermia Pedigrees. Hum. Mol. Genet. 6, 953-961.
154. Sakamoto, N.; Hidaka, K.; Fujisawa, T.; Maeda, M. and Iuchi, I. (1998) Identification of a Point Mutation associated with a Silent Phenotype of Human Serum Butyrylcholinesterase--A Case of Familial Cholinesterasemia. Clin. Chim. Acta 274, 159-166.
155. Sambuughin, N.; Nelson, T. E.; Jankovic, J.; Xin, C.; Meissner, G.; Mullakandov, M.; Ji, J.; Rosenberg, H.; Sivakumar, K. and Goldfarb, L. G. (2001) Identification and Functional Characterization of a Novel Ryanodine Receptor Mutation Causing Malignant Hyperthermia in North American and South American Families. Neuromuscul. Disord. 11, 530-537.
156. Schwab, M.; Marx, C.; Zanger, U. M.; Eichelbaum, M. and Fischer-Bosch, M. (2002) Pharmakogenetik der Zytochrom-P-450-Enzyme: Bedeutung für Wirkungen und Nebenwirkungen von Medikamenten. Deutsches Aertzeblatt 99, A497-504.
157. Schwinn, D. A. and Booth, J. V. (2002) Genetics Infuses New Life into Human Physiology: Implications of the Human Genome Project for Anaesthesiology and Peri-operative Medicine. Anesthesiology 96, 261-263.
158. Seefelder, C. and Leeder, J. S. (2002) Cytochrome P450 Pharmacogenetics and Anaesthesia. Paediatr. Anesth. 12, 810-811.
159. Sei, Y.; Brandom, B. W.; Bina, S.; Hosoi, E.; Gallagher, K. L.; Wyre, H. W.; Pudimat, P. A.; Holman, S. J.; Venzon, D. J.; Daly, J. W. and Muldoon, S. (2002) Patients with Malignant Hyperthermia Demonstrate an Altered Calcium Control Mechanism in B Lymphocytes. Anesthesiology 97, 1052-1058.
160. Sei, Y.; Gallagher, K. L. and Basile, A. S. (1999) Skeletal Muscle Type Ryanodine Receptor is Involved in Calcium Signalling in Human B Lymphocytes. J. Biol. Chem. 274, 5995-6002.
161. Shastri, K. A.; Logue, G. L.; Stern, M. P.; Rehman, S. and Raza, S. (1997) Complement Activation by Heparin-Protamine Complexes during Cardiopulmonary Bypass: Effect of C4A Null Allele. J. Thorac. Cardiovasc. Surg. 114, 482-488.
162. Siddiqui, A.; Kerb, R.; Weale, M. E.; Brinkmann, U.; Smith, A.; Goldstein, D. B.; Wood, N. W. and Sisodiya, S. M. (2003) Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter Gene ABCB1. N. Engl. J. Med. 348, 1442-1448.
163. Sindrup, S. H. and Brosen, K. (1995) The Pharmacogenetics of Codeine Hypoalgesia. Pharmacogeneties 5, 335-346.
164. Singh, D. (2003) Ethical Issues of Pharmacogenetics must be Addressed, Says Nuffield Council. Bmj 327, 701.
165. Sofowora, G. G.; Dishy, V.; Muszkat, M.; Xie, H. G.; Kim, R. B.; Harris, P. A.; Prasad, H. C.; Byrne, D. W.; Nair, U. B.; Wood, A. J. and Stein, C. M. (2003) A Common Beta1-Adrenergic Receptor Polymorphism (Arg389Gly) Affects Blood Pressure Response to Beta-Blockade. Clin. Pharmacol. Ther. 73, 366-371.
166. Stamer, U. M.; Lehnen, K.; Hothker, F.; Bayerer, B.; Wolf, S.; Hoeft, A. and Stuber, F. (2003) Impact of CYP2D6 Genotype on Postoperative Tramadol Analgesia. Pain 105, 231-238.
167. Steegmuller, H. (1975) On the Geographical Distribution of Pseudocholinesterase Variants. Humangenetik 26, 167-185.
168. Stewart, S.; Hogan, K.; Rosenberg, H. and Fletcher, J. (2001) Identification of the Arg1086His Mutation in the Alpha Subunit of the Voltage-dependent Calcium Channel (CACNA1S) in a North American Family with Malignant Hyperthermia. Clin. Genet. 59, 178-184.
169. Substance Abuse and Mental Health Services Administration (2003) Overview of Findings from the 2002 National Survey on Drug Use and Health. Office of Applied Studies, NHSDA Series H-21, DHHS Publication No. SMA 03-3774.
170. Sudo, K.; Maekawa, M., Kanno, T.; Akizuki, S. and Magara, T. (1996) Three Different Point Mutations in the Butyrylcholinesterase Gene of Three Japanese Subjects with a Silent Phenotype: Possible Japanese Type Alleles. Clin. Biochem. 29, 165-169.
171. Takahashi, H. and Echizen, H. (2003) Pharmacogenetics of CYP2C9 and Interindividual Variability in Anticoagulant Response to Warfarin. Pharmacogenomics J. 3, 202-214.
172. Tardiff, B. E.; Newman, M. F.; Saunders, A. M.; Strittmatter, W. J.; Blumenthal, J. A.; White, W. D.; Croughwell, N. D.; Davis, R. D., Jr.; Roses, A. D. and Reves, J. G. (1997) Preliminary Report of a Genetic Basis for Cognitive Decline after Cardiac Operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann. Thorac. Surg. 64, 715-720.
173. Tilgen, N.; Zorzato, F.; Halliger-Keller, B.; Muntoni, F.; Sewry, C.; Palmucci, L. M.; Schneider, C.; Hauser, E.; Lehmann-Horn, F.; Muller, C. R. and Treves, S. (2001) Identification of Four Novel Mutations in the C-Terminal Membrane Spanning Domain of the Ryanodine Receptor 1: Association with Central Core Disease and Alteration of Calcium Homeostasis. Hum. Mol. Genet. 10, 2879-2887.
174. 2+ Release is Altered by 15 Calcium Release Channel (Ryanodine Receptor) Mutations associated with Malignant Hyperthermia and/or Central Core Disease. J. Biol. Chem. 272, 26332-26339.
175. Tunek, A. and Svensson, L. A. (1988) Bambuterol, A Carbamate Ester Prodrug of Terbutaline, as Inhibitor of Cholinesterases in Human Blood. Drug Metab. Dispos. 16, 759-764.
176. Uhl, G. R.; Sora, I. and Wang, Z. (1999) The mu Opiate Receptor as a Candidate Gene for Pain: Polymorphisms, Variations in Expression, Nociception and Opiate Responses. Proc. Natl. Acad. Sci. USA 96, 7752-7755.
177. Urwyler, A.; Deufel, T.; McCarthy, T. and West, S. (2001) Guidelines for Molecular Genetic Detection of Susceptibility to Malignant Hyperthermia. Br. J. Anesth. 86, 283-287.
178. Viskin, S. (1999) Long QT Syndromes and Torsade de Pointes. Lancet 354, 1625-1633.
179. Weinshilboum, R. (2003) Inheritance and Drug Response. N. Engl. J. Med. 348, 529-537.
180. White, P. F. (2002) Rapacuronium: Why did it Fail as a Replacement for Succinylcholine? Br. J. Anesth. 88, 163-165.
181. Wilson, S. G.; Bryant, C. D.; Lariviere, W. R.; Olsen, M. S.; Giles, B. E.; Chesler, E. J. and Mogil, J. S. (2003) The Heritability of Antinociception II: Pharmacogenetic Mediation of Three Over-The-Counter Analgesics in Mice. J. Pharmacol. Exp. Ther. 305, 755-764.
182. Xin, L. and Wang, Z. J. (2002) Bioinformatic Analysis of the Human mu Opioid Receptor (OPRM1) Splice and Polymorphic Variants. AAPS Pharm. Sci. 4, 23.
183. Yanagihara, Y.; Kariya, S.; Ohtani, M.; Uchino, K.; Aoyama, T.; Yamamura, Y. and Iga, T. (2001) Involvement of CYP2B6 in N-demethylation of Ketamine in Human Liver Microsomes. Drug Metab. Dispos. 29, 887-890.
184. Yang, T.; Ta, T. A.; Pessah, I. N. and Allen, P. D. (2003) Functional Defects in Six Ryanodine Receptor Isoform-1 (Ryr1) Mutations associated with Malignant Hyperthermia and their Impact on Skeletal Excitation-Contraction Coupling. J. Biol. Chem. 278, 25722-25730.
185. Yoshida, A. and Motulsky, A. G. (1969) A Pseudocholinesterase Variant (E Cynthiana) associated with Elevated Plasma Enzyme Activity. Am. J. Hum. Genet. 21, 486-498.
186. Zanger, U. M.; Fischer, J.; Raimundo, S.; Stuven, T.; Evert, B. O.; Schwab, M. and Eichelbaum, M. (2001) Comprehensive Analysis of the Genetic Factors Determining Expression and Function of Hepatic CYP2D6. Pharmacogenetics 11, 573-585.
187. Zee, R. Y.; Hoh, J.; Cheng, S.; Reynolds, R.; Grow, M. A.; Silbergleit, A.; Walker, K.; Steiner, L.; Zangenberg, G.; Fernandez-Ortiz, A.; Macaya, C.; Pintor, E.; Fernandez-Cruz, A.; Ott, J. and Lindpainter, K. (2002) Multi-locus Interactions Predict Risk for Post-PTCA Restenosis: An Approach to the Genetic Analysis of Common Complex Disease. Pharmacogenomics J. 2, 197-201.
188. Zhang, Y.; Chen, H. S., Khanna, V. K.; De Leon, S.; Phillips, M. S.; Schappert, K.; Britt, B. A.; Browell, A. K. and MacLennan, D. H. (1993) A Mutation in the Human Ryanodine Receptor Gene associated with Central Core Disease. Nat. Genet. 5, 46-50.
189. Ziegeler, S.; Tsusaki, B. E. and Collard, C. D. (2003) Influence of Genotype on Peri-operative Risk and Outcome. Anesthesiology 99, 212-219.
190. Zorzato, F.; Scutari, E.; Tegazzin, V.; Clementi, E. and Treves, S. (1993) Chlorocresol: An Activator of Ryanodine Receptor-Mediated Ca2+ Release. Mol. Pharmacol. 44, 1192-1201.
191. Zorzato, F.; Yamaguchi, N.; Xu, L.; Meissner, G.; Muller, C. R.; Pouliquin, P.; Muntoni, F.; Sewry, C.; Girard, T. and Treves, S. (2003) Clinical and Functional Effects of a Deletion in a COOH-Terminal Lumenal Loop of the Skeletal Muscle Ryanodine Receptor. Hum. Mol. Genet. 12, 379-388.
192. Zubieta, J. K.; Heitzeg, M. M.; Smith, Y. R.; Bueller, J. A.; Xu, K.; Xu, Y.; Koeppe, R. A.; Stohler, C. S. and Goldman, D. (2003) COMT val158met Genotype Affects mu-Opioid Neurotransmitter Responses to a Pain Stressor. Science 299, 1240-1243.